Summary
Kimberly-Clark plans to buy Kenvue, the maker of Tylenol, for over $40 billion in a cash-and-stock deal. This purchase aims to make Kimberly-Clark a major player in consumer health and wellness products. The deal is expected to be completed in the second half of next year.
Key Facts
- Kimberly-Clark plans to buy Kenvue for more than $40 billion.
- Kenvue makes products like Tylenol, Band-Aid, and Zyrtec.
- Kimberly-Clark makes Kleenex, Huggies, and major toilet paper brands.
- The deal is a mix of cash and stock, valuing Kenvue at about $48.7 billion.
- Kenvue shareholders will receive approximately $21 per share.
- Kimberly-Clark's stock dropped over 10% after the announcement.
- Kenvue faces a lawsuit in Texas over alleged drug risks.
- Kimberly-Clark and Kenvue expect to finish the deal in the second half of next year.
